ID Number		2766
Study Type		Human / Provocation
Model		Electrohypersensitivity (EHS) self-reporting patients were serially included in the present prospective study for oxidative stress and antioxidative stress response assessment.
Details		Abstract: Irigaray, Caccamo and Belpomme (2018): A total of 32 electrohypersensitivity (EHS) selfreporting patients were serially included in the present prospective study for oxidative stress and antioxidative stress response assessment. All thiobarbituric acidreactive substances (TBARs) were measured in the plasma, particularly malondialdehyde (MDA) for lipid peroxidation; additional measurements included total thiol group molecules, reduced glutathione (GSH), oxidized glutathione (GSSG) for oxidative stress assessment and nitrotyrosine, a marker of peroxynitriteinduced oxidative/nitrosative stress. In addition, the activity of CuZn superoxide dismutase (SOD1) was measured in red blood cells (RBCs) and glutathione reductase (GR) and glutathione peroxidase (GPx) in RBCs and plasma. Depending of the biomarker considered, 3050% of EHS selfreporting patients presented statistically significantly increased TBARs, MDA, GSSG and NTT mean plasmatic level values in comparison with normal values obtained in healthy controls (P<0.0001). By contrast, there were no plasmatic level values above the upper normal limits for GSH, GSH/GSSG ratio, total glutathione (GluT) and GSH/GluT ratio, and values for these GSHassociated biomarkers were statistically significantly decreased in 2040% of the patients (P<0.0001). Furthermore, in RBCs, mean SOD1 and GPx activities were observed to be statistically significantly increased in ~60% and 19% (P<0.0001) of the patients, respectively, while increased GR activity in RBCs was observed in only 6% of the patients. The present study reports for the first time, to the best of our knowledge, that overall ~80% of EHS selfreporting patients present with one, two or three detectable oxidative stress biomarkers in their peripheral blood, meaning that these patientsas is the case for cancer, Alzheimer's disease or other pathological conditionspresent with a true objective new pathological disorder.
Findings		Not Applicable to Bioeffects
Status		Completed With Publication
Principal Investigator		Paris V University Hospital, France
Funding Agency		?????
Country		FRANCE
References		Irigaray, P et al. International Journal of Molecular Medicine., (2018) 42:1885-1898 Belpomme, D et al. Int J Mol Sci., (2020) 21:1915- Belpomme, D et al. Rev Environ Health., (2015) 30:251-271 Belpomme, D et al. Int J Mol Sci., (2021) 22:7321- Belpomme, D et al. Environmental Research., (2022) 212(PtA):113374-
Comments